Shots:
Ethris has dosed the first pts in a P-IIa trial of ETH47 for asthma symptom reduction after rhinovirus challenge, building on P-I trial data, which showed strong respiratory tract activity, local IFNλ induction, antiviral gene activation, & no systemic exposure
The P-IIa trial will evaluate ETH47 vs PBO in ~50 adults with asthma who…
